Man Group
ORMP icon

Man Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Man Group’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-55,316
Closed -$665K – 2196
2022
Q4 		$665K Sell
55,316
-15,649
-22% -$122K ﹤0.01% 1432
2022
Q3 		$460K Buy
+70,965
New +$574K ﹤0.01% 1541
2022
Q2 		– Sell
-15,600
Closed -$83.4K – 1645
2022
Q1 		$135K Buy
+15,600
New +$160K ﹤0.01% 2019
2021
Q4 		– Sell
-37,285
Closed -$820K – 2062
2021
Q3 		$820K Buy
37,285
+23,485
+170% +$400K ﹤0.01% 1396
2021
Q2 		$185K Buy
+13,800
New +$158K ﹤0.01% 1814

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SIGI
Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Man Group's ORMP Position: Q1 2023 in Review

Man Group sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 55,316 shares — an estimated $665K sold.

Man Group first reported a position in ORMP in Q2 2021 and held it in 5 quarters. The position peaked at $820K in Q3 2021. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

  • Man Group reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Man Group sold 55,316 Oramed Pharmaceuticals shares in Q1 2023, an estimated $665K.
  • Man Group first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Man Group's Oramed Pharmaceuticals position peaked at $820K in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.